RT Journal Article
SR Electronic
T1 The genetic architecture of Alzheimer disease risk in the Ohio and Indiana Amish
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21259932
DO 10.1101/2021.07.06.21259932
A1 Osterman, Michael D.
A1 Song, Yeunjoo E.
A1 Adams, Larry D.
A1 Laux, Renee A.
A1 Caywood, Laura J.
A1 Prough, Michael B.
A1 Clouse, Jason E.
A1 Herington, Sharlene D.
A1 Slifer, Susan H.
A1 Lynn, Audrey
A1 Fuzzell, M. Denise
A1 Fuzzell, Sarada L.
A1 Hochstetler, Sherri D.
A1 Miskimen, Kristy
A1 Main, Leighanne R.
A1 Dorfsman, Daniel A.
A1 Ogrocki, Paula
A1 Lerner, Alan J.
A1 Ramos, Jairo
A1 Vance, Jeffery M.
A1 Cuccaro, Michael L.
A1 Scott, William K.
A1 Pericak-Vance, Margaret A.
A1 Haines, Jonathan L.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259932.abstract
AB Alzheimer disease (AD) is the most common type of dementia and is currently estimated to affect 6.2 million Americans. It ranks as the sixth leading cause of death in the United States and the proportion of deaths due to AD has been increasing since the year 2000 while the proportion of many other leading causes of deaths have decreased or remained constant. The risk for AD is multifactorial, including genetic and environmental risk factors. Though APOE remains the largest genetic risk factor for AD, more than 26 other loci have been associated with AD risk. Here, we recruited from a population of Amish adults from Ohio and Indiana to investigate AD risk and protective genetic effects. With slightly lower incidence and later age of onset, it is thought that the Amish may hold protective genetic variants for AD. As a founder population that typically practices endogamy, variants that are rare in the general population may be at higher frequency in the Amish population. We characterized the genetic architecture of AD risk in the Amish and compared this to a non-Amish population, elucidating the lower relative importance of APOE and differing genetic architecture of the Amish compared to a general European ancestry population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by National Institutes of Health / National Institute on Aging, grant AG058066 (to Jonathan L. Haines, Margaret A. Pericak-Vance, and William K. Scott).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted under human subjects protocols approved by the University of Miami and Case Western Reserve University/University Hospitals Institutional Review Boards (ID 03-16-12).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available through NIAGADS (https://www.niagads.org/) upon publication.